Mini Review
In this review paper, we discuss the clinical utility of total insulin-like growth factor-I (IGF I) and that of IGF binding protein-3 (IGFBP-3).
IGF-I and IGFBP-3 are well known to be dependent on GH and are thought to be useful in the evaluation of short children (1-10). We discuss methods of measurements of these parameters, and their clinical utility in the evaluation of short children. Part of this review paper has been published in our previous papers (6-11). If an assay for free IGF-I is available widely, we may not have to think over accurate measurements of total IGF-I by removing IGFBPs.
Methods
We have recently reported a newly developed IRMA for free IGF-I (15-17 IRMA (data not shown)(27). So far, other than in pregnant sera, IGFBP-3 proteolytic activity was reported to be present in seminal plasma (31) , sera from patients with GH receptor dysfunction (32) and sera from various catabolic conditions (33) (34) (35) .
In this review paper, we measured total IGF-I levels by RIA after acid-ethanol extraction (8, 9, 13). The standard of the IGF-I assay was recombinant IGF-I. IGFBP-3 was measured by
Blum's RIA method with minor modifications (9, 36). The standards of IGFBP-3 assays were pooled serum calibrated to purified IGFBP-3
given by Dr. Mark Stene (Endocrine Sciences)(7-9, 36). The cutoff levels of IGF-I and IGFBP-3 for diagnosing GHD at each age (5th percentile) are shown in Table 1 .
IGF-I and IGFBP-3 in Short Children Table 1 The cutoff levels (5th percentile) of IGF-I and IGFBP-3 (ng/mL, mg/L, respectively)
Clinical utility of total IGF-I and IGFBP-3 in the evaluation of short children In this section we would like to show: 1) total IGF-I and IGFBP-3 measurements are useful in the diagnosis of GHD and evaluation of GH secretion, 2) total IGF-I and IGFBP-3 measurements can replace growth hormone (GH) provocation tests as laboratory parameters in the diagnosis of GHD and evaluation of GH secretion, 3) comparison of total IGF-I and IGFBP-3 in the evaluation of GH secretion. 1) Total IGF-I and IGFBP-3 measurements are useful in the diagnosis of GHD and evaluation of GH secretion In order to analyse the clinical utility of total IGF-I, we compared the results of total IGF-I measurements with those of GH provocation tests in short children (IGF-I means total IGF-I in the rest of this paper, unless defined differently). The short children subjects were divided into three groups: (1) complete GHD (CGHD): all the GH peaks of GH provocation tests were less than 5 ng/mL, (2) partial GHD (PGHD): the highest GH peak among more than two GH provocation tests was from 5 to 10 ng/mL, (3) normal short children (NS): at least one GH peak was over 10 ng/mL. More than two kinds of GH provocation tests were done. The false positive ratio of arginine and insulin tests, which means that one of the GH peaks was more than 10 ng/mL, whereas the other GH peak was less than 10 ng/mL in short children, were 25 % and 19 %, respectively (37) . The specificity of IGF-I for NS with normal IGFBP-3 was 91 % (n=65). These data suggest that IGF-I is one of the best screening parameters in the evaluation of short children.
Similar studies were done by using two groups of short children to clarify the clinical utility of IGFBP-3. One group is CGHD with low IGF-I and the other is NS with normal IGF-I.
The sensitivity of IGFBP-3 for CGHD with low IGF-I was 98 % (n=52). The specificity of IGFBP-3 for NS with normal IGF-I was 80 % (n=81). These data suggest that IGFBP-3 is also one of the best screening parameters in the evaluation of short children.
So far IGF-I and IGFBP-3 levels were analysed, basically, in comparison with the results of GH provocation tests, which we believe was not the best method to study IGF-I and IGFBP-3 utility in the evaluation of GH secretion. GH provocation tests have been used traditionally but they can not be a gold standard in the diagnosis of GHD (11). In addition, any cut-off criteria for GHD is arbitrary judging from the fact that GH secretion is continuous from zero to normal (or acromagalic). Indeed, we have reported that there are considerable overlaps in height, IGF-I levels, and IGFBP-3 levels between PGHD and NS, if those diagnoses are based on results of GH provocation tests (9). Thus, in order to check the clinical utility of IGF-I and IGFBP-3, we have analysed IGF-I and IGFBP-3 a little differently in the following paragraph.
The correlations of a response to a conventional GH treatment (0.5 U/kg/week, 6-7 time a week) with pretreatment IGF-I and IGFBP-3 levels (standard deviation scores; SDS), were studied. The subjects were 46 prepubertal short children (less than-2 SDS at the time of the initiation of GH treatment) who had been treated for at least 1 year. A significant correlation between pretreatment IGF-I SDS and incremental height gain (= height velocity after GH treatment-height velocity before GH treatment) was obtained (r=0.48, P=0.008). As shown in Fig. 2 , a more significant correlation between pretreatment IGFBP-3 SDS and incremental height gain was also obtained (r=0.80, P=0.0001). If the assumption that the less the GH secretion in short children is, the more they grow with a conventional GH treatment is true, these significant correlations indicate that IGF-I and IGFBP-3, in particular IGFBP-3, can reflect GH secretion status, thus IGFBP-3 measurements are useful in the evaluation of GH secretion.
So far we have explained that IGF-I and IGFBP-3 measurements are useful in the evaluation of GH secretion. However, GH provo-
and IGFBP-3 in Short Children 2) Can total IGF-I and IGFBP-3 measurements replace GH provocation tests as laboratory parameters in the diagnosis of GHD and evaluation of GH secretion?
Our simple answer to this question is yes. We can say "yes" very clearly in diagnosing severe type of GHD. For example, if he or she had (a) hard auxological data such as height velocity of less than 3.5 cm/year (arbitrary criteria) or height SDS of less than-3.5 SDS necessarily on direct measurements of arginine vasopressin during hypertonic saline loading tests. Lastly, we have to stress the importance of clinical data, especially auxological data. GHD is diagnosed based on both clinical and laboratory data as is true in other endocrine diseases. We have explained the utility of IGF parameters as laboratory data in the evaluation of GH secretion. However, clinical data, in particular, auxological data are much more important than laboratory data in the evaluation of GH secretion. No laboratory data can be justified in the absence of suggestive clinical data.
3) Comparison
of total IGF-I and IGFBP-3 levels in the evaluation of GH secretion IGF-I and IGFBP-3 classified subjects differently in 15 % of patients with GHD and 21 % of those with NS as will be explained in detail, although overall, the correlation of IGF-I and IGFBP-3 by using sera of 238 normal, normal short, and GHD children was significant (r=0.74, P<0.0005). Among 108 patients with GHD (9), 92 patients had concordant IGF-I and IGFBP-3 levels in terms of above and below the cutoff levels (28 patients are both above and 64 patients are both below), whereas 16 patients (15 %) had discordant results (7 patients showed IGF-I levels below the cutoff levels with IGFBP-3 levels above the cutoff levels and 9 showed the opposite situation for IGF-I and IGFBP-3). The discordant ratio of CGHD (4/59) was lower than that of PGHD (12/49). Similarly, among 103 patients with NS (9), 81 patients (79 %) had concordant results of IGF-I and IGFBP-3 (65 patients are both above and 16 are both below), whereas 22 patients (21 %) had discordant results (6 patients showed IGF-I levels below IGF-I and IGFBP-3 in Short Children the cutoff levels with IGFBP-3 levels above the cutoff levels and 16 showed the opposite situation for IGF-I and IGFBP-3). These data suggest that measuring both IGF-I and IGFBP-3 may improve diagnostic accuracy for GHD. Another explanation of these discordant results of IGF-I and IGFBP-3 may be due to a limitation of GHD diagnosis based on GH stimulation tests, since about 20 % of GHD and NS had normal levels of both IGF parameters and low levels of them, respectively. The other possibility for these discordant results is a difference in intradaily variation and the effect of nutrition between these parameters. The IGFBP-3 values may well be considered in the diagnosis of GHD rather than the IGF-I values in the younger age. Indeed, in CGHD patients of the younger age group (less than 10 years old) in our previous report (8), all the IGFBP-3 levels were below the age-related cutoff levels, whereas 79 % of IGF-I levels were below the age-related cutoff levels. This difference (100 % for IGFBP-3 vs 79 % for IGF-I) might be due to the relatively higher normal IGFBP-3 values at younger ages than IGF-I values or due to the limitation of IGF-I measurements in terms of removing IGFBPs specially at low levels of IGF-I. A similar advantage of IGFBP-3 over IGF-I especially at young ages was reported by Blum et al. and Yokoya et al. using different subjects (3, 26).
It remains to be established whether IGFBP-3 is less useful in the older age groups than in the younger. The difference in the ratio of the GHD patients who had IGFBP-3 levels above the age-related cutoff levels between the younger and older age groups (the ratio was lower in a young age group), again noted in our previous report (8), may be due to the influence 
